• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Marrone Bio Innovations Inc. (Amendment)

    7/15/22 9:12:06 AM ET
    $MBII
    Major Chemicals
    Basic Industries
    Get the next $MBII alert in real time by email
    SC 13D/A 1 ea162756-13da12ospraie_marr.htm AMENDMENT NO. 12 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 12)*

     

     

     

    Marrone Bio Innovations, Inc.

    (Name of Issuer)

     

    Common Stock, $0.00001 par value

    (Title of Class of Securities)

     

    57165B106

    (CUSIP Number)

     

    Ospraie Ag Science LLC

    c/o Dwight Anderson

    437 Madison Avenue, 28th Floor

    New York, NY 10022

    (212) 602-5000 

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    July 12, 2022

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 57165B106 SCHEDULE 13D  

     

    1  

    NAME OF REPORTING PERSON

     

    Ospraie Ag Science LLC

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☐

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    WC, OO (see Item 3)

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

      7  

    SOLE VOTING POWER

     

    0

      8  

    SHARED VOTING POWER

     

    0

      9  

    SOLE DISPOSITIVE POWER

     

    0

      10  

    SHARED DISPOSITIVE POWER

     

    0

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

     

    0

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0% (1)

    14  

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) As a result of the closing of the merger contemplated by that certain Agreement and Plan of Merger dated as of March 16, 2022 by and among Marrone Bio Innovations, Inc. (the “Issuer”), Bioceres Crop Solutions Corp. and BCS Merger Sub, Inc. (such merger, the “Merger”), which Merger closed on July 12, 2022, the reporting persons no longer beneficially own, as of immediately following the closing of the Merger, any shares of the common stock of the Issuer.

     

    2

     

    CUSIP No. 57165B106 SCHEDULE 13D  

     

    1  

    NAME OF REPORTING PERSON

     

    Ospraie Management, LLC

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☐

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    OO

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

      7  

    SOLE VOTING POWER

     

    0

      8  

    SHARED VOTING POWER

     

    0

      9  

    SOLE DISPOSITIVE POWER

     

    0

      10  

    SHARED DISPOSITIVE POWER

     

    0

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

     

    0

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0% (1)

    14  

    TYPE OF REPORTING PERSON

     

    IA, OO

     

    (1) As a result of the closing of the Merger, the reporting persons no longer beneficially own, as of immediately following the closing of the Merger, any shares of the common stock of the Issuer.

     

    3

     

    CUSIP No. 57165B106 SCHEDULE 13D  

     

    1  

    NAME OF REPORTING PERSON

     

    Ospraie Holding I, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☐

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    OO

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

      7  

    SOLE VOTING POWER

     

    0

      8  

    SHARED VOTING POWER

     

    0

      9  

    SOLE DISPOSITIVE POWER

     

    0

      10  

    SHARED DISPOSITIVE POWER

     

    0

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

     

    0

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0% (1)

    14  

    TYPE OF REPORTING PERSON

     

    PN, HC

     

    (1) As a result of the closing of the Merger, the reporting persons no longer beneficially own, as of immediately following the closing of the Merger, any shares of the common stock of the Issuer.

     

    4

     

    CUSIP No. 57165B106 SCHEDULE 13D  

     

    1  

    NAME OF REPORTING PERSON

     

    Ospraie Management, Inc.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☐

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    OO

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

      7  

    SOLE VOTING POWER

     

    0

      8  

    SHARED VOTING POWER

     

    0

      9  

    SOLE DISPOSITIVE POWER

     

    0

      10  

    SHARED DISPOSITIVE POWER

     

    0

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

     

    0

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0% (1)

    14  

    TYPE OF REPORTING PERSON

     

    CO, HC

     

    (1) As a result of the closing of the Merger, the reporting persons no longer beneficially own, as of immediately following the closing of the Merger, any shares of the common stock of the Issuer.

     

    5

     

    CUSIP No. 57165B106 SCHEDULE 13D  

     

    1  

    NAME OF REPORTING PERSON

     

    OAS MM, LLC

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☐

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    OO

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

      7  

    SOLE VOTING POWER

     

    0

      8  

    SHARED VOTING POWER

     

    0

      9  

    SOLE DISPOSITIVE POWER

     

    0

      10  

    SHARED DISPOSITIVE POWER

     

    0

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

     

    0

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0% (1)

    14  

    TYPE OF REPORTING PERSON

     

    HC, OO

     

    (1) As a result of the closing of the Merger, the reporting persons no longer beneficially own, as of immediately following the closing of the Merger, any shares of the common stock of the Issuer.

     

    6

     

    CUSIP No. 57165B106 SCHEDULE 13D  

     

    1  

    NAME OF REPORTING PERSON

     

    Dwight Anderson

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☐

    3  

    SEC USE ONLY

     

    4  

    SOURCE OF FUNDS

     

    AF, PF, OO (see Item 3)

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

      7  

    SOLE VOTING POWER

     

    0

      8  

    SHARED VOTING POWER

     

    0

      9  

    SOLE DISPOSITIVE POWER

     

    0

      10  

    SHARED DISPOSITIVE POWER

     

    0

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

     

    0

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0% (1)

    14  

    TYPE OF REPORTING PERSON

     

    IN, HC

     

    (1) As a result of the closing of the Merger, the reporting persons no longer beneficially own, as of immediately following the closing of the Merger, any shares of the common stock of the Issuer.

     

    7

     

     

    Amendment No. 12 to Schedule 13D

     

    The following constitutes Amendment No. 12 (“Amendment No. 12”) to the Schedule 13D filed with the Securities and Exchange Commission (“SEC”) by Ospraie Ag Science LLC and Dwight Anderson on February 12, 2018, as amended by Amendment No. 1 filed on August 12, 2019, Amendment No. 2 filed on September 5, 2019, Amendment No. 3 filed on December 20, 2019, Amendment No. 4 filed on January 3, 2020, Amendment No. 5 filed on March 6, 2020, Amendment No. 6 filed on April 16, 2020, Amendment No. 7 filed on May 1, 2020, Amendment No. 8 filed on October 13, 2020, Amendment No. 9 filed on December 17, 2020, Amendment No. 10 filed on March 16, 2021, and Amendment No. 11 filed on December 17, 2021. This Amendment No. 12 amends and supplements the Schedule 13D as specifically set forth herein.

     

    All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

     

    ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

     

    Item 3 of the Schedule 13D is supplemented and superseded, as the case may be, as follows:

     

    The disclosure in Item 4 is incorporated herein by reference.

     

    ITEM 4. PURPOSE OF TRANSACTION

     

    Item 4 of the Schedule 13D is supplemented and superseded, as the case may be, as follows:

     

    On July 12, 2022, as a result of the closing of the merger (the “Merger”) contemplated by that certain Agreement and Plan of Merger dated as of March 16, 2022 by and among Marrone Bio Innovations, Inc. (the “Issuer”), Bioceres Crop Solutions Corp. (“Bioceres”) and BCS Merger Sub, Inc., all of the 70,836,258 shares of the Common Stock of the Issuer beneficially owned by the Reporting Persons immediately prior to the closing of the Merger were cancelled and extinguished and automatically converted into the right to receive 6,233,590 ordinary shares of Bioceres. Following the closing of the Merger, the Reporting Persons no longer beneficially own any shares of the Common Stock of the Issuer. As a result of the Merger, the Issuer became a wholly-owned subsidiary of Bioceres.

     

    Except as set forth herein, the Reporting Persons have no present plan or proposal that would relate to or result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D.

     

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

     

    Item 5 of the Schedule 13D is hereby amended and restated as follows:

     

    (a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Schedule 13D are incorporated herein by reference. Such information is based on the fact that, as a result of the closing of the Merger on July 12, 2022, the Reporting Persons no longer beneficially own, as of immediately following the closing of the Merger, any shares of the Common Stock of the Issuer.

     

    (c) Except as disclosed in this Schedule 13D, as amended, the Reporting Persons did not effect any transactions in the Common Stock of the Issuer during the past sixty days.

     

    (d) No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.

     

    (e) Not applicable.

     

    ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

     

    Item 6 of the Schedule 13D is supplemented and superseded, as the case may be, as follows:

     

    The disclosure in Item 4 is incorporated herein by reference.

     

    8

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: July 15, 2022

     

    OSPRAIE AG SCIENCE LLC  
         
    By: OAS MM, LLC,  
      its managing member  
         
    By: /s/ Dwight Anderson  
    Name: Dwight Anderson  
    Title: Managing Member  
       
    OSPRAIE MANAGEMENT, LLC  
         
    By: Ospraie Holding I, LP,  
      its managing member  
         
    By: Ospraie Management, Inc.,  
      its general partner  
         
    By: /s/ Dwight Anderson  
    Name: Dwight Anderson  
    Title: Sole Owner  
       
    OSPRAIE HOLDING I, LP  
         
    By: Ospraie Management, Inc.,  
      its general partner  
         
    By: /s/ Dwight Anderson  
    Name: Dwight Anderson  
    Title: Sole Owner  
       
    OSPRAIE MANAGEMENT, INC.  
         
    By: /s/ Dwight Anderson  
    Name: Dwight Anderson  
    Title: Sole Owner  
         
    OAS MM, LLC  
         
    By: /s/ Dwight Anderson  
    Name: Dwight Anderson  
    Title: Managing Member  
       
    DWIGHT ANDERSON  
         
    By: /s/ Dwight Anderson  

     

     

    9

     

     

    Get the next $MBII alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MBII

    DatePrice TargetRatingAnalyst
    9/22/2021$2.00Buy
    Roth Capital
    8/19/2021$3.50 → $2.50Buy
    Aegis Capital
    More analyst ratings

    $MBII
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ROTH MKM's Agribusiness Investment Banking Group Sees Success with the Closing of Three M&A Sellside Transactions

      ROTH MKM ("Roth"), www.roth.com, a relationship-driven investment bank focused on serving growth companies and their investors, is pleased to announce that their agribusiness investment banking group has advised on three sellside transactions in the past nine months. The transactions included business models in the areas of cover crops, gene editing, biologicals, bio stimulants, and alternative fertilizers, and demonstrate the group's expertise in designing and executing M&A processes to achieve the best outcomes for its clients in a wide array of agriculture related sectors. ROTH MKM's Agribusiness Investment Banking Group served as the sellside advisor on the following transactions:

      4/11/23 9:00:00 AM ET
      $BG
      $BIOX
      $CTVA
      $CVX
      Packaged Foods
      Consumer Staples
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions Completes Merger With Marrone Bio, Creating a Global Leader in Sustainable Agricultural Solutions

      Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. (NASDAQ:MBII) ("MBI"). "The completion of this transaction represents an important milestone in our journey, cementing our leadership in the development and commercialization of sustainable agricultural solutions," said Bioceres Chief Executive Officer, Federico Trucco. "MBI brings 15 years of experience in the development of biological solutions, and we are excited to a

      7/12/22 4:43:00 PM ET
      $BIOX
      $MBII
      Agricultural Chemicals
      Industrials
      Major Chemicals
      Basic Industries
    • Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp.

      RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI's stockholders approved the adoption of the Merger Agreement and approved on a non-binding advisory basis certain executive compensation that may be paid or become payable in connection with the merger contemplated by t

      7/11/22 8:30:00 AM ET
      $BIOX
      $MBII
      Agricultural Chemicals
      Industrials
      Major Chemicals
      Basic Industries

    $MBII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Marrone Bio Innovations Inc. (Amendment)

      SC 13D/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)

      7/15/22 9:12:06 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form SC 13G/A filed by Marrone Bio Innovations Inc. (Amendment)

      SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)

      3/29/22 11:21:42 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form SC 13G/A filed by Marrone Bio Innovations Inc. (Amendment)

      SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)

      2/14/22 12:25:35 PM ET
      $MBII
      Major Chemicals
      Basic Industries

    $MBII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on Marrone Bio Innovations with a new price target

      Roth Capital initiated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.00

      9/22/21 11:59:03 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • Aegis Capital reiterated coverage on Marrone Bio Innovations with a new price target

      Aegis Capital reiterated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.50 from $3.50 previously

      8/19/21 9:34:56 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • Canaccord Genuity resumed coverage on Marrone Bio Innovations with a new price target

      Canaccord Genuity resumed coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $3.50

      3/5/21 7:31:59 AM ET
      $MBII
      Major Chemicals
      Basic Industries

    $MBII
    Leadership Updates

    Live Leadership Updates

    See more
    • 180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors

      MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Pamela Marrone, PhD, and Frank Knuettel II, MBA, to its Board of Directors (“Board”) effective upon the earlier of (a) the business day following the filing of the 2020 Form 10-K Annual Report; and (b) June 28, 2021. The Board also changed the effective dates of the appointments of Russell T. Ray, MBA and Teresa DeLuca MD, MBA as members of the Board, as previously announced

      6/10/21 9:12:32 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • Marrone Bio Appoints Sue Cheung New Chief Financial Officer

      DAVIS, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, announced today that Suping (Sue) Cheung has been appointed chief financial officer, effective Feb. 18, 2021. She succeeds James Boyd, who previously announced his intention to retire. Cheung, a certified public accountant, brings to Marrone Bio 28 years of experience in international strategic and financial operations, including financial reporting, forecasting and budgeting; mergers and acquisitions; equity and debt financing; internal controls; and inves

      1/28/21 9:00:00 AM ET
      $QUIK
      $MBII
      Semiconductors
      Technology
      Major Chemicals
      Basic Industries

    $MBII
    SEC Filings

    See more
    • SEC Form 15-12G filed by Marrone Bio Innovations Inc.

      15-12G - Pro Farm Group, Inc. (0001441693) (Filer)

      9/2/22 6:17:10 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form EFFECT filed by Marrone Bio Innovations Inc.

      EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)

      8/30/22 12:15:26 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form EFFECT filed by Marrone Bio Innovations Inc.

      EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)

      8/30/22 12:15:28 AM ET
      $MBII
      Major Chemicals
      Basic Industries

    $MBII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Vasavada Amit was granted 129,184 shares and returned 285,892 shares to the company, closing all direct ownership in the company

      4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)

      7/15/22 11:15:05 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form 4: Johnson Timothy B was granted 102,167 shares and returned 212,374 shares to the company, closing all direct ownership in the company

      4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)

      7/15/22 11:13:32 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • SEC Form 4 filed by Ospraie Ag Science Llc

      4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)

      7/15/22 9:09:02 AM ET
      $MBII
      Major Chemicals
      Basic Industries

    $MBII
    Financials

    Live finance-specific insights

    See more
    • Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results

      RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: Higher sales of row crop products in the first quarter were somewhat offset by lower sales into specialty crop markets, which were affected by adverse weather conditions. Based on the strength of current orders, revenues in the first half are expected to increase in the low- to mid-teens on a percentage basis.Gross profit of $6.2 million and gross margins of 55.9% reflected changes in product mix, higher raw material

      5/11/22 4:01:00 PM ET
      $BIOX
      $MBII
      Agricultural Chemicals
      Industrials
      Major Chemicals
      Basic Industries
    • Marrone Bio Innovations to Report First Quarter 2022 Results on Wednesday, May 11 at 4:30 p.m. Eastern Time

      RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2022, after market close on Wednesday, May 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations' first quarter financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information: Q1 2022 Conference Call and Webcast Date: Wednesday, May 11, 2022Time: 4:30 p.m

      4/27/22 8:00:00 AM ET
      $MBII
      Major Chemicals
      Basic Industries
    • Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results

      RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.For the full year, net loss was $16.6 million and Adjusted EBITDA1 loss was $8.7 million, improvements of 17.9% and 21.2%, respectively.As announced March 16, 2022, Marrone Bio and Bioceres Crop So

      3/28/22 4:01:00 PM ET
      $BIOX
      $MBII
      Agricultural Chemicals
      Industrials
      Major Chemicals
      Basic Industries